Targeting TRPV1 for Cancer Pain Relief: Can It Work?
Chronic intractable pain affects a large proportion of cancer patients, especially those with metastatic bone disease. Blocking sensory afferents for cancer pain relief represents an attractive alternative to opioids and other drugs acting in the CNS in that sensory nerve blockers are not addictive...
Main Author: | Arpad Szallasi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-02-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/16/3/648 |
Similar Items
-
Resiniferatoxin: Nature’s Precision Medicine to Silence TRPV1-Positive Afferents
by: Arpad Szallasi
Published: (2023-10-01) -
Carcinogenesis and Metastasis: Focus on TRPV1-Positive Neurons and Immune Cells
by: Nuray Erin, et al.
Published: (2023-06-01) -
Molecular Surgery Concept from Bench to Bedside: A Focus on TRPV1+ Pain-Sensing Neurons
by: László Pecze, et al.
Published: (2017-06-01) -
Resiniferatoxin: The Evolution of the “Molecular Scalpel” for Chronic Pain Relief
by: Dorothy Cimino Brown
Published: (2016-08-01) -
Unveiling the mechanisms of neuropathic pain suppression: perineural resiniferatoxin targets Trpv1 and beyond
by: Safa Shehab, et al.
Published: (2023-11-01)